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Alzheimer’s disease (AD) is hypothesized to be caused by the amyloid-β protein (Aβ), which 
aggregates into β-sheet structure to form thick, twisted fibrils that deposit in the brain as insoluble 
plaques.  Thus, finding inhibitors that prevent or reduce the aggregation of Aβ would be one 
therapeutic strategy for fighting this disease.  Gold nanoparticles are ideal candidates for this 
therapeutic strategy for AD.  Nanoparticles are small enough for human cells to uptake but won’t 
induce cell death.  Nanoparticles can also cross the blood-brain barrier (BBB) at low 
concentrations.  Thus, we investigated the inhibitory capabilities of gold nanoparticles by 
performing monomer aggregation assays using gold nanospheres with three different coatings: 
citrate, poly (acrylic acid) (PAA), and poly (allylamine hydrochloride) (PAH).  Aβ monomer was 
incubated in the presence or absence of nanospheres and agitated to promote aggregation.  β-sheet 
aggregates formed were monitored using thioflavin T (ThT), a fluorescent dye that binds the β-
sheet structure of amyloid aggregates but not random coil monomer to yield an enhanced signal.  
Results demonstrate that gold nanospheres do inhibit Aβ aggregate formation, and this inhibition is 
influenced by both surface coating and nanoparticle size.  18 nm PAA coated nanospheres were 
identified as potent inhibitors, capable of abrogating aggregation at a substoichiometric ratio of 
1:200.
Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative 
disorder that results in memory loss, unusual behavior, 
inabilities to think or process, and, eventually, death [1].  AD 
patients also exhibit behavioral problems, such as agitation, 
irritability, and aggression, which make it more difficult for 
the caregivers to deal with the patients.  AD patients 
eventually lose themselves in confusion, are unable to 
recognize their loved ones, and gradually become unable to 
carry on their basic daily function, thus requiring 24/7 
standby-assistants, contributing emotional and economic 
burden to their families.  Because the risk of AD exacerbates 
with age, and since the life expectancy is increasing, this 
brings an even bigger challenge to health care.  Currently, it is 
estimated that there are 25-30 million AD patients worldwide, 
and studies suggest that the number of AD cases will triple by 
2040 [2].  With the growing population and an increasing life 
expectancy, a therapeutic strategy for AD is even more dire 
than ever.   
 This devastating disease was first discovered by and named 
after Dr. Alois Alzheimer.  In 1901, he admitted a 51-year old 
patient, named Auguste D. with progressive memory loss, 
hallucination, and delusion.  Intrigued by such odd behaviors, 
Dr. Alzheimer investigated her brain post-mortem and found 
unusual deposits in the brain tissues that he identified as 
neuritic plaques [3].  These plaques were later found to be 
comprised of the amyloid-β protein (Aβ).  Soluble Aβ 
monomer aggregates to form insoluble Aβ fibrils that deposit 
in the brain as plaques.  These cytotoxic plaques could trigger 
microglial activation followed by neuritic degeneration [2].  
Such degeneration leads to neuronal loss, causing the brains 
of AD patients to weigh one-third less than that of normal 
aging subjects [4]. Another study suggests that accumulation 
of Aβ deposits at synaptic terminals may cause synaptic 
damage related to cognitive decline [5].  Therefore, finding 
inhibitors that prevent or reduce the aggregation of Aβ is one 
therapeutic strategy for fighting this disease. 
 Nanoparticles have been explored for their utility in a 
number of medical applications.  Nanoparticles have been 
used for cell imaging, targeted drug delivery, cancer 
diagnostics and therapeutic applications [6].  In applications 
of AD treatment, nanoparticles are attractive candidates as a 
result of their demonstrated ability to penetrate the blood 
brain barrier (BBB) [7]. In fact, nanoparticles have been 
shown to affect Aβ aggregation.  Yoo et al. demonstrate a 
promotion of Aβ aggregation by N-isopropylacrylamide and 
N-tert-butylacrylamide copolymeric nanoparticles as well as 
cerium oxide nanoparticles.  These researchers hypothesize 
that electrostatic interactions between nanoparticles and 
proteins lead to an increased local protein concentration in the 
vicinity of the nanoparticles, which accelerates the nucleation-
dependent aggregation process.  In contrast, cadmium 
telluride (CdTe) nanoparticles have been shown to slow the 
rate of Aβ aggregation by binding protein to deplete the 
 
                                                                                                       Journal of the South Carolina Academy of Science, [2011], 9(2)   
 
15 
amount of free monomers available for aggregate formation 
[8]. 
 In addition, Cabaleiro-Logo et al. report that copolymeric 
nanoparticles of varying hydrophobicity not only prevent 
aggregation by binding to monomeric Aβ and prefibrillar 
oligomers but also reverse the aggregation of Aβ fibrils 
formed in absence of these nanoparticles [9].     
 In the current study, we explore the ability of spherical gold 
nanoparticles (AuNPs) to attenuate Aβ aggregation.  Spherical 
AuNPs are an ideal candidate as an AD therapeutic because 
they are small enough for human cells to uptake (10) and are 
not cytotoxic (10, 11).  In addition, AuNP can be easily 
characterized using UV-Vis spectrophotometry and 
transmission electron microscopy (TEM) [6]. 
 We investigated the inhibitory capabilities of AuNPs with 
three different surface coatings: citrate, poly (acrylic acid) 
(PAA), and poly (allylamine hydrochloride) (PAH).  We 
demonstrate that both surface coating and nanoparticle size 
can influence inhibitory capabilities.  Furthermore, we 
identify 18 nm PAA coated AuNPs as strong inhibitors of Aβ 
aggregation that are capable of abrogating aggregate 
formation at a substoichiometric ratio of 1:200. 
Materials and Methods 
Materials 
Aβ1-40 peptide, thioflavin T (ThT), and bovine serum albumin 
(BSA) were purchased from Anaspec, Inc. (San Jose, CA), 
Sigma (St. Louis, MO), and EMD Biosciences (San Diego, 
CA), respectively.  
Aβ1–40 Monomer Purification 
Aβ1-40 monomer was purified to remove small aggregates that 
could serve as nucleation seeds.  Aβ1-40 protein was stored 
desiccated at -20°C.  The protein was solubilized to a 
concentration of 2 mg/mL in 50 mM NaOH and purified via 
size exclusion chromatography (SEC) on a Superdex 75 
HR10/300 column (GE Healthcare, Buckinghamshire, UK).  
Prior to Aβ1-40 monomer purification, the column was 
equilibrated in 40 mM Tris-HCl, pH 8.0, and pretreated with 2 
mg/mL BSA to reduce any nonspecific interaction between 
the column matrix and the peptide.  UV-Vis absorbance (276 
nm) was used to calculate the purified Aβ1-40 monomer 
concentration using an extinction coefficient  
of 1450 M-1·cm-1. 
Aβ1–40 Monomer Aggregation 
SEC-purified Aβ1-40 monomer at a concentration of 40 µM 
was incubated alone (control) or with 0.02 nM, 0.1 nM, or 0.2 
nM gold nanoparticles in 40 mM Tris-HCl, pH 8.0.  These 
solutions were agitated via vortexing at 800 rpm and 25°C to 
promote aggregation.  β-sheet aggregate formation was 
monitored using ThT, a fluorescent dye that binds the β-sheet 
structure of amyloid aggregates but not random coil monomer 
to yield an enhanced signal. Periodically, an aliquot was 
diluted eightfold into 10 µM ThT and the fluorescence was 
measured using an LS-45 luminescence spectrometer (Perkin–
Elmer,Waltham, MA) with excitation at 450 nm and emission 
from 470 nm to 500 nm. Fluorescence values were determined 
as the area under the emission peak. 
 Aβ monomer aggregation exhibits three distinct phases:  
lag, growth, and plateau.  During the lag phase, nucleation 
occurs, followed by a growth phase during which the amount 
of β-sheet aggregate increases rapidly.  Eventually, the 
aggregation process reaches a plateau, where monomers and 
aggregates of different sizes are in equilibrium.  An effective 
inhibitor will reduce the height of the plateau.  Reduction of 
the equilibrium plateau for aggregate formation, PR, is 





where FI is the fluorescence of the plateau observed in the 
presence of the inhibitor and FC is the fluoresce of the plateau 
observed for the control. 
Gold Nanoparticles 
8 nm and 18 nm gold nanoparticles (AuNP) were a kind 
gift from the laboratory of Dr. Rahina Mahtab at South Carolina 
State University. As shown in Figure 1, AuNPs with four 
different coatings were tested for their inhibitory capabilities.  
AuNPs were created by a series of surface overcoatings. First, 
following the Frens method, the reduction of hydrogen 
tetrachloroaurate (III) trihydrate (HAuCl4) by sodium citrate 
created negatively charged citrate coated AuNPs.  For poly 
(acrylic acid) (PAA) AuNPs, 3 nm citrate AuNPs were 
synthesized via the reduction of HAuCl4 by sodium borohydride 
and then capped with sodium citrate.  Using ascorbic acid, a 
solution of HAuCl4 and hexadecyltrimethylammonium bromide 
(CTAB) was weakly reduced and then added to the 3 nm seeds to 
increase their diameter, growing from 8 nm to 18 nm (12).  Once 
the CTAB particles were created to the desired size, PAA was 
overcoated onto the particles to yield negatively charged PAA 
AuNPs.  PAA AuNPs were overcoated to yield positively 










Figure 1.  Citrate AuNPs overcoated with CTAB, PAA, and PAH to yield 
AuNPs with different surface properties. 
Results and Discussion  
When Aβ1-40 monomer was aggregated in the presence of 
negatively charged citrate coated AuNPs, the fluorescence of 
the equilibrium plateau was decreased, indicating inhibition 
leading to a reduction in the extent of aggregate formation 
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(Figure 2).  This effect was dose dependent, ranging from no 
inhibition in the presence of 0.02 nM nanoparticles to 26 ± 
13% inhibition in the presence of 0.1 nM nanoparticles.  
Further increase of the citrate coated nanoparticle 
concentration to 0.2 nM, however, failed to increase 
inhibitory capabilities.  
 The fluorescence of the equilibrium plateau was also 
decreased when Aβ1-40 monomer was aggregated in the 
presence of PAH coated AuNPs, again indicating reduced 
aggregate formation (Figure 3).  As for PAH coated AuNPs, 
this effect was dose dependent, ranging from 8 ± 3% 
inhibition in the presence of 0.025 nM nanoparticles to 42 ± 
0% inhibition in the presence of 0.2 nM nanoparticles. 
Furthermore, these positively charged AuNPs were more 
effective inhibitors than citrate coated nanoparticles.   
 When Aβ1-40 monomer was aggregated in the presence of 
negatively charged PAA coated AuNPs, any increase in 
fluorescence was abrogated, demonstrating complete 
inhibition of aggregate formation (Figure 4).  Furthermore, 
this effect extended down to a concentration of 0.02 nM, a 
concentration that represents a substoichiometric ratio of 









Figure 2.  Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl 
alone (solid circle, control) or in the presence of 0.02 nM (open squares), 
0.1 nM (open triangles), or 0.2 nM (open circles) citrate coated AuNPs.  
Aggregation was induced via vortexing at 25°C and monitored using ThT 
fluorescence.  Results are representative of three independent 
experiments. 
 
Figure 3.  Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl 
alone (solid circles, control) or in the presence of 0.025 nM (open 
squares) or 0.2 nM (open triangles) PAH overcoated AuNPs.  
Aggregation was induced via vortexing at 25°C and monitored using ThT 










 Figure 4.  Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl 
alone (solid circles, control) or in the presence of 0.02 nM (open squares), 
0.1 nM (open triangles), or 0.2 nM (open circles) PAA overcoated 
AuNPs.  Aggregation was induced via vortexing at 25°C and monitored 
using ThT fluorescence. Results are representative of three independent 
experiments. 
 
Table 1.  Inhibition of Aβ1-40 monomer aggregation by AuNPs with 
citrate, PAA, and PAH coatings. 
AuNP coating [AuNP] % Inhibition1 
0.02 nM 0 ± 0% 
0.1 nM 26 ± 13% Citrate 
0.2 nM 30 ± 2% 
0.025 nM 8 ± 3% 
PAH 
0.2 nM 42 ± 0% 
0.02 nM 100 ± 0% 
0.1 nM 100 ± 0% PAA 
0.2 nM 100 ± 0% 
1Monomer aggregation was performed in the presence of 18 nm AuNPs 
as in Figures 2-4.  % Inhibition was calculated as the reduction in the 
fluorescence plateau at equilibrium, PR, using Eq. 1.  Results represent 
the average of three independent experiments. 
 Thus, all three surface modified AuNPs were found to 
inhibit aggregation of Aβ1-40 monomer in a dose dependent 
manner (Table 1).  Furthermore, the extent of inhibition was 
influenced by surface overcoating, with negatively charged 
PAA coated nanoparticles exhibiting the most pronounced 
effects.  These results are in agreement with the findings of 
Yoo et al. for CdTe nanoparticles [8] and Cabaleiro-Logo et al 
for copolymeric nanoparticles, where inhibition of Aβ 
aggregation was observed (9).  These findings suggest that 
surface coated AuNPs may bind monomeric or oligomeric Aβ 
to reduce the concentration of the protein available for 
aggregation. 
 To explore the effect of nanoparticle size on inhibitory 
capabilities, PAA coated AuNPs with different diameters were 
investigated for their ability to inhibit Aβ1-40 monomer 
aggregation. When the diameter of PAA coated AuNPs was 
reduced to 8 nm, their ability to inhibit Aβ1-40 aggregation was 
 
                                                                                                       Journal of the South Carolina Academy of Science, [2011], 9(2)   
 
17 
significantly reduced.  Compared to the complete inhibition 
observed in the presence of 0.2 nM PAA coated AuNPs with a 
diameter of 18 nm, 8 nm PAA coated AuNPs were capable of 
reducing the fluorescence plateau by only 39 ± 19% (Figure 5, 
Table 2).  This difference may result from the smaller surface 
area presented by smaller diameter AuNPs, reducing the 










Figure 5.  Aβ1-40 monomer (40 µM) was incubated in 40 mM Tris-HCl 
alone (solid circles, control) or in the presence of 8 nm (open squares) or 
18 nm (open triangles) PAA overcoated AuNPs present at a concentration 
of 0.2 nM.  Aggregation was induced via vortexing at 25°C and 
monitored using ThT fluorescence.  Results are representative of three 
independent experiments. 
Table 2.  Inhibition of Aβ1-40 monomer aggregation by 8 nm and 18 nm 
PAA coated AuNPs. 
AuNP diameter [AuNP] % Inhibition1 
8 nm 0.2 nM 39 ± 19 % 
18 nm 0.2 nM 100 ± 0 % 
1Monomer aggregation was performed in the presence of PAA overcoated 
AuNPs as in Figure 5.  % Inhibition was calculated as the reduction in the 
fluorescence plateau at equilibrium, PR, using Eq. 1.  Results represent 
the average of three independent experiments.  
 
Conclusions 
The current study demonstrates that surface coated gold 
nanospheres are capable of inhibiting aggregation of Aβ, a 
process hypothesized to play a role in the progression of AD.  
Furthermore, both the surface coating and nanoparticle size 
play a role in the ability of AuNPs to intervene with the 
process of amyloid aggregation.  These effects may stem from 
variations in the ability of AuNPs to interact with Aβ 
monomer or small oligomers and reduce the quantity of Aβ 
available for aggregation.  Of particular significance, 
complete inhibition of 40 µM Aβ1-40 monomer aggregation 
was observed in the presence of 0.02 nM PAA overcoated 
AuNPs.  When considered relative to the low nanomolar 
concentrations of Aβ present in vivo, this 1:200 
substoichiometric ratio represents an extremely low AuNP 
inhibitor concentration, which might be effectively delivered 
across the BBB.  Together, these results suggest that AuNPs 
should be further explored as a therapeutic strategy for AD.   
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